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Abstract
Purpose The supercapsular percutaneously-assisted total hip
(SuperPath) surgical technique for total hip replacement
(THR) is a tissue-sparing approach that has been shown to
improve key variables associated with the economic burden
of THR (e.g., length of stay, readmissions). To date, no studies
have examined the economic impact of using this technique in
the United States. The objective of this study was to compare
the in-hospital costs of this technique to all other THRs per-
formed in a large hospital system in the United States.
Methods The costing database for a large hospital system was
retrospectively searched for all in-hospital costs associated
with primary THRs performed between January 2013 and
September 2015. Data for all SuperPath THRs (group A) were
compared to that of all other THRs performed at centres with-
in the hospital system (group B).
Results Use of the SuperPath technique resulted in significant
overall in-hospital cost reductions of 15.0 % (p < 0.000), in-
cluding reductions in operating room costs of 17.3 %
(p < 0.000), physical/occupational therapy costs of 26.8 %
(p = 0.005), and pharmacy costs of 25.3 % (p < 0.000).
Length of stay (1.2 vs. 2.6 days), transfusion rates (1.9 vs.
15.8 %), and 30-day readmission rates (0.4 vs. 2.9 %) were
also lower in group A.
Conclusions The use of this tissue-sparing surgical technique
resulted in reductions in in-hospital costs, length of stay, and
readmissions when compared to all other THRs performed in
a large hospital system in the United States.
Keywords Economic outcomes . Supercapsular
percutaneously-assisted total hip . Tissue-sparing . Total hip
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Introduction
The supercapsular percutaneously-assisted total hip
(SuperPath) surgical technique for total hip replacement
(THR) is a tissue-sparing approach that utilizes the interval
between the piriformis and the gluteus medius to access the
hip capsule [1, 2]. By accessing the hip capsule through this
interval, the surgeon is able to preserve musculature and the
external rotators vital for allowing early ambulation and re-
ducing the opportunity for post-operative dislocation [3–5]. A
recent multicenter study found use of this technique reduced
several key factors associated with the economic burden of
THR including reductions in length of stay (LOS) of over
50% (1.6 vs. 3.3 days) and 30-day readmission rates of nearly
2 % (2.3 vs. 4.2 %) when compared to previously reported
averages in the United States [6]. Another study showed re-
ductions of in-hospital costs of over 28 % at a centre in
Canada when using SuperPath compared to the Hardinge ap-
proach [7]. While these reports suggest in-hospital costs could
be reduced in the United States using this technique, there
have yet to be any studies to confirm. The purpose of the
current study was to compare the economic burden of this
surgical technique to that of all other THRs performed in a
large hospital system based in the United States.
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Methods
The costing database for a large hospital system was retro-
spectively searched for all in-hospital costs associated with
primary THRs performed between January 2013 and
September 2015. Data was compiled in two groups. Group
A consisted of all procedures performed by a single surgeon
using the SuperPath technique and group B included all other
THRs performed within the same hospital system. Group B
included data for 34 surgeons at nine hospitals in four states.
THRs were included in the analyses if they had an ICD-9-CM
primary procedure code of 81.51, an MS-DRG code of 470,
and primary ICD-9-CM diagnosis codes of 715.15, 715.25, or
715.35. These criteria were selected to ensure the two groups
were similar in diagnosis and disease severity, as group A only
had two cases with an MS-DRG code different than 470 and
only five cases with a diagnosis code different from those
stated.
Only costs incurred by the hospital were collected and not
charges or reimbursement values. Costing information was
collected related to all aspects of the primary in-hospital stay
including: anesthesia; intensive care unit; imaging; labs; oper-
ating room (OR) time; pharmacy; recovery room; patient
room and board; physical/occupational therapy; and transfu-
sions. Patient LOS, transfusion rate, redamission rate, and
discharge status were also collected. LOS was defined as the
number of nights a patient stayed in the hospital. The transfu-
sion rate was described as the percentage of patients requiring
a transfusion. Readmission rate was the percentage of patients
readmitted to the hospital for any reason within 30 days
following discharge. Discharge status indicated the patient
disposition (e.g., routinely home, skilled nursing facility).
Statistical methods
Age and LOS were presented as means and ranges.
Transfusion rate, readmission rate, and discharge statuses
were all presented as percentage of the total number of pa-
tients in each group. The mean per patient category costs for
each group and the percent difference between the groups
were calculated. Percent differences were used instead of ac-
tual costs to protect proprietary costing information for the
hospital system. When appropriate, a t-test (α = 0.05) was
used to compare per patient costs between the two groups.
Results
Patient population
A total of 419 group A and 1673 group B THRs fulfilled the
inclusion criteria (Table 1). Group Awas younger (61.5 years
vs. 65.1 years, p < 0.000) and had a higher percentage of male
patients (47.4 vs. 43.9 %). Patients in group A experienced a
54 % reduction in LOS (1.23 vs. 2.68 days, p < 0.000) when
compared to group B and over 61 % more where discharged
routinely home (91.1 vs. 29.6 %). Operating room (p = 0.004)
and anesthesia time (p = 0.002) were both significantly re-
duced in group A.
Table 1 Patient demographics,
LOS, transfusion rate,
readmission rate, and discharge
status for the two study groups
Group A Group B
N patients 419 1673
Mean age (years)* 61.5 (range, 26–90) 65.1 (range, 20–90)
Males/females 199/220 735/938
Operating room time (mins)* 142.7 (range, 88–322) 148.1 (range, 62–430)
Anesthesia time (mins)* 142.5 (range, 88–274) 148.7 (range, 62–430)
Length of stay (days)* 1.23 (range, 0.5–4.7) 2.68 (range, 0.0–17.2)
Transfusions (%) 8 (1.9 %) 265 (15.8 %)
30-day readmissions (%) 2 (0.4 %) 50 (2.9 %)
Discharge status
Home or self care 382 (91.1 %) 496 (29.6 %)
SNF 7 (1.6 %) 349 (20.8 %)
Home health care 10 (2.3 %) 707 (42.2 %)
Rehabilitation facility 4 (0.9 %) 113 (6.7 %)
Another hospital 0 (0.0 %) 3 (0.17 %)
Court/law enforcement 0 (0.0 %) 3 (0.17 %)
Hospital in-patient care 0 (0.0 %) 1 (0.05 %)
Death 0 (0.0 %) 1 (0.05 %)
*significant difference (p < 0.05)
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In-hospital costs
Overall per patient costs were 15.0 % higher in group B.
Table 2 shows the percent difference in per patient costs for
each individual cost category. Group B was significantly more
costly than group A in all categories except for recovery room,
laboratory, ICU, and implant costs. Pharmacy costs were
25.3 % higher in group B. When only costs associated with
opioids/opiates were analyzed, group B THRs incurred
49.2 % more costs. Implant costs accounted for the largest
percent of the in-hospital costs and were not significantly dif-
ferent between the two groups (p = 0.065). When implant
costs were excluded from the analysis, overall per patient
costs were 36.1 % higher in group B.
30-day readmissions
There were two readmissions (0.4 %) in group A. The first
was a 68 year old female patient readmitted for a
periprosthetic fracture. The patient was revised and sent to a
rehabilitation facility 2.9 days after surgery. The second read-
mission was a 50 year old female admitted for psychoses
secondary to bipolar disorder. This readmission was not asso-
ciated with the THR and the patient was discharged to home
4.3 days after readmission.
There were 50 readmissions (2.9 %) in group B (Table 3).
The most common reasons for readmission were infection
(1.31 %) and periprosthetic fracture (0.53 %). There were 30
females and 20males readmitted, which aligned with the over-
all gender distribution of group B. The mean LOS for
readmissions in group B was 4.28 days (range, 0.6–25.0)
and patients were discharged to home (16.0 %), SNF
(34.0 %), home health care (30.0 %), rehabilitation (14.0 %),
or a long-term hospital (4.0 %). One patient (2.0 %) died
during their readmission stay.
Discussion
Results from the current study show use of the SuperPath
technique was associated with a reduction in in-hospital
costs of 15.1 %. The cost difference increased to 36.1 %
when implant costs were excluded. This agreed well with
a recent study from Canada showing a 28.4 % reduction
in in-hospital costs, excluding implants, when using
SuperPath compared to the traditional lateral approach
[7]. The current study is the first to examine the economic
impact of using this technique in the United States.
Anesthesia, operating room, and physical/occupational
therapy costs were all significantly higher in group B. The
reduction in anesthesia costs seen in group A was possibly
due to the procedure not requiring the use of blocks or
regional anesthesia, which are commonly used in THR.
Operating room cost reductions could be due to the de-
creased need for surgical assistants compared to tradition-
al THR techniques or the need for expensive specialty
tables or apparatuses as required by some techniques
(e.g., some variants of the direct anterior approach) [8,
9]. The SuperPath technique was performed with a single
surgical assistant without the need for any specialty tables
or apparatuses in all cases. As mentioned previously, both
operating and anesthesia times were reduced approximate-
ly six minutes in group A. It is unlikely though, that such
a small improvement alone would result in such high cost
reductions.
Pharmacy costs were 25.3 % higher in group B and
when only opioid costs were examined the difference
Table 2 Per patient cost comparison between two groups
Cost category Per patient percent difference p-value
Overall costs Group B +15.0 % <0.000*
Implants Group A +2.8 % 0.065
Costs excluding implants Group B +36.1 % <0.000*
OR room Group B +17.3 % <0.000*
Anesthesia Group B +79.4 % <0.000*
Room and board Group B +26.4 % <0.000*
Recovery room Group A +12.8 % <0.000*
Physical/occupational therapy Group B +26.8 % 0.005*
Pharmacy Group B +25.3 % <0.000*
Opioids Group B +49.2 % <0.000*
Imaging Group B +23.0 % <0.000*
Laboratory Group A +3.9 % 0.147
ICU Group B +45.0 % 0.322
Transfusions Group B +88.2 % <0.000*
*significant difference
Table 3 Reasons for readmission for groups A and B
Reason for readmission Group A Group B
Infection 0 (0.00 %) 22 (1.31 %)
Periprosthetic fracture 1 (0.23 %) 9 (0.53 %)
Hematoma 0 (0.00 %) 5 (0.29 %)
Dislocation 0 (0.00 %) 5 (0.29 %)
Wound complications 0 (0.00 %) 2 (0.11 %)
Other 0 (0.00 %) 2 (0.11 %)
Femoral neck fracture 0 (0.00 %) 1 (0.05 %)
Fever 0 (0.00 %) 1 (0.05 %)
Implant breakage 0 (0.00 %) 1 (0.05 %)
Vertigo 0 (0.00 %) 1 (0.05 %)
Psychoses 1 (0.23 %) 0 (0.00 %)
Cerebral artery occlusion 0 (0.00 %) 1 (0.05 %)
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increased to 49.2 %. These costs included any drug deliv-
ered during the hospital stay. The reduction in pharmacy
costs was likely multifactorial. Only oral medications
were used in group A patients. No patient-controlled an-
algesia or boutique medications (e.g., intravenous Tylenol
or Exparel) were used in any group A patients. Finally,
the use of minimally-invasive or tissue-sparing techniques
has been shown to reduce pain levels and the amount of
pain medication consumed [10–12]. Therefore, it is likely
that the group A patients consumed less pain medication,
and in particular powerful opioids, on average due to the
sparing of the musculature and surrounding soft tissues.
The transfusion rate in group A was nearly 14 % lower
than that of group B, resulting in mean transfusion cost
savings of 88.2 %. Transfusion rates can be affected by
several factors including the amount of soft tissue damage
caused by the surgical technique. As previously men-
tioned, the SuperPath technique does not require the cut-
ting of muscles or tendons by utilizing the interval be-
tween the piriformis and the gluteus medius. Another fac-
t o r a f f e c t i ng t r a n s f u s i on r a t e s i s t h e u s e o f
antifibrinolytics. In group A, 95.9 % of patients received
aminocaproic acid and the remaining 4.1 % received
tranexamic acid. Nearly a third (33.2 %) of patients in
group B received tranexamic acid and 27.7 % received
aminocaproic acid. When examining only those patients
receiving aminocaproic acid, the transfusion rate was
1.7 % (7 of 402) in group A and 7.4 % (35 of 470) in
group B. This suggests the surgical technique and not
choice of antifibrinolytics could be responsible for the
reduction in the need for transfusions. Only a single study
could be found compar ing the effec t iveness of
aminocaproic and tranexamic acid for preventing transfu-
sions following joint replacement [13]. That study found
nearly five times (12.5 vs. 2.8 %) as many aminocaproic
acid patients required transfusion as did tranexamic acid
patients. Interestingly in the current study, 7.4 % (35 of
470) of group B patients receiving aminocaproic acid and
20.5 % (114 of 557) of group B patients receiving
tranexamic acid required transfusions.
Over 91 % of patients in group A were routinely
discharged home compared with just 29.6 % of group B.
While discharge status does not affect in-hospital costs, it
does have a potentially significant impact on costs for
hospitals participating in bundling. Bozic et al. reported
over 35 % of charges associated with a 30-day episode of
care were related to post-discharge care, with 70 % of
postdischarge payments due to discharging patients to
post-acute care facilities [14]. Ramos et al. reported the
average costs for discharge to an inpatient rehabilitation
facility, skilled nursing facility, and home with care as
$16,464, $6,678, and $4,239, respectively [15]. These
studies emphasize the potential significant benefit of
reducing inpatient rehabilitation facility discharges from
6.7 % in group B to 0.9 % in group A. Similar to dis-
charge status, readmission rates do not impact in-hospital
costs but are significant in a bundling scenario. Bozic
et al. also reported the cost burden of unplanned THR
readmissions to be 4.3 % and the average costs of each
readmission to be $17,103 [16]. The readmission rate for
group A was over seven times lower than that of group B
(0.4 vs. 2.9 %) in the current study.
While the current study is a review of data indepen-
dently collected by a hospital system on a large group of
patients, there are several limitations. The two groups had
some differences in population characteristics. Group A
was nearly four years younger and had 3.5 % more male
patients. Efforts were made to control the indications and
diagnoses for the procedure during patient selection
criteria, but not all aspects could be controlled. There
was a single surgeon performing the SuperPath procedure
and it is therefore possible that the skill of the surgeon
and not the technique itself could bias results. There are
multiple surgeons included in group B and there are a
number of factors (e.g., surgical technique, implant selec-
tion, surgeon skill) that could affect results. There are also
multiple hospitals included in group B and therefore dif-
ferences in conditions or procedures (e.g., indications for
transfusion) at each of these centers could affect costs.
A final limitation is that this study does not include the
learning curve associated with the SuperPath technique, as
the single surgeon had significant previous experience
with the technique. Costs during the learning curve with
a technique can be higher due to the potential for in-
creased LOS, transfusions, surgical time, complications,
and readmissions. The previously mentioned study com-
paring the SuperPath technique to the traditional lateral
included the initial 49 SuperPath surgeries performed by
the author [7]. This study found complication rates and
associated in-hospital costs were all lower in the
SuperPath group even during this learning curve phase.
In conclusion, the use of the SuperPath technique re-
sulted in reductions of in-hospital costs, LOS, and
readmissions when compared to all other THRs per-
formed in a large hospital system in the United States.
Additionally, over 60 % more patients were discharged
directly home. Future studies are needed to determine
the economic impact of this technique across an entire
30-day episode of care and to compare to specific surgical
techniques.
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